Sign in
Not yet taking people in NetherlandsPhase 1/2

Tests a dual-label PSMA tracer to guide prostate cancer surgery

Tests a radioactive and fluorescent PSMA tracer to guide surgery in prostate cancer.

Key facts

Who runs it
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
DUAL
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
13 people, planned
Started
1 Aug 2025
Expected to end
1 Aug 2027
Type of study
Interventional
Record updated
11 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer confirmed by a tissue test, who had a PSMA PET/CT scan showing the tumour and who can have robot-assisted prostate surgery with lymph node removal.

Age
18 years and older
Sex
Men only
Disease stage
Adenocarcinoma of the prostate confirmed by tissue examination, with a tumour that takes up the PSMA tracer on PET/CT; no minimum or maximum number of lesions.
Earlier treatment
A routine PSMA PET/CT within 90 days before surgery. No earlier radiotherapy of the abdomen, no earlier or current chemotherapy or immunotherapy, and no androgen deprivation therapy now or within 6 months before surgery.
Biomarker or test result
Tumour that takes up the PSMA tracer on PSMA PET/CT.

Main reasons for not taking part

  • Earlier radiotherapy of the abdomen
  • Androgen deprivation therapy now or within 6 months before surgery
  • Another cancer within 5 years before surgery (skin cancers excepted)
  • Earlier or current chemotherapy or immunotherapy
  • Reduced kidney function (eGFR below 60ml/min/1,73m2)

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male, aged 18 years and older
  • Histopathologically confirmed adenocarcinoma of the prostate
  • Had a routine PSMA PET/CT within 90 days before surgery
  • PSMA avid tumor on PSMA PET/CT
  • Suitable for RALP +ePLND, as per institutional guidelines (no minimum or maximum lesions on PSMA PET)
  • Written and signed informed consent

Who cannot take part

  • Previous radiotherapy of the abdomen
  • Ongoing androgen deprivation therapy (ADT) or within 6 months prior to surgery
  • Previous or ongoing chemotherapy
  • Previous or ongoing immunotherapy
  • History of other malignancy within 5 years prior to surgery (except skin malignancies)
  • History of clinically significant allergies including anaphylaxis
  • History of impaired renal function (defined as eGFR<60ml/min/1,73m2)
  • Severe claustrophobia interfering with PET/CT or SPECT/CT scanning

Where in Netherlands

  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To confirm lesion-specific uptake of 99mTc-hPSMA by PCa

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
99mTechnetium and Cyanine-5 (HybriD) Prostate Specific Membrane Antigen (PSMA) Tracer-gUided Surgery in ProstAte Cancer - a FeasibiLity Study (DUAL study)
Plain-language title
Tests a dual-label PSMA tracer to guide prostate cancer surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 July 2025